BeOne Medicines AG (NASDAQ:ONC) is one of the best healthcare stocks to buy in 2026. On January 13, at the 44th Annual JP Morgan Healthcare Conference, BeOne Medicines AG (NASDAQ:ONC) reiterated significant progress in the development of its product portfolio.
BRUKINSA, a tyrosine kinase inhibitor, has achieved a six-year progression-free survival of 74%, compared with 32% with bendamustine plus rituximab, in treatment-naive chronic lymphocytic leukemia. Sonrotoclax, its BCL2 inhibitor, received regulatory approval, with an overall response rate of 86% in heavily pretreated CLL patients. The company is also advancing 15 new molecular entities into clinical trials and plans to deliver 8 to 10 additional candidates.
Early Jan. 7, Citizens reiterated a market perform rating and $396 price target on the stock, impressed by strong efficacy data from the company’s Phase 3 trial in gastric cancer patients. The expected approval of sonrotoclax, a next-generation BCL2 inhibitor, is also expected to trigger additional approval globally. Likewise, the research firm expects the company’s Brukinsa drug to generate $3.8 billion in 2025.
BeOne Medicines AG (NASDAQ:ONC) is a biotechnology company focused on discovering, developing and commercializing innovative and affordable oncology treatments. It is known for products such as Brukinsa and Tevimbra and uses a global network for R&D and manufacturing.
While we recognize ONC’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock. READ NEXT: The 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: 12 Best Stock Picks. Disclosure: None. This article was originally published in Internal jumpsuit.